Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.58 |
| ▸ | P4HB | P07237 | 3/20 | 0.55 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9965606 | 0.92 | MDM2 (0.58) | TP53MAPTSMN1; SMN2MDM2P4HB | |
| SCHEMBL9965688 | 0.90 | P4HB (0.63) | SMN1; SMN2MDM2P4HBRCE1 | |
| SCHEMBL9965691 | 0.89 | MDM2 (0.75) | MDM2P4HB | |
| SCHEMBL15870294 | 0.88 | MDM2 (0.60) | TP53MAPTSMN1; SMN2MDM2P4HB | |
| SCHEMBL9965604 | 0.87 | MDM2 (0.66) | MDM2P4HB | |
| SCHEMBL9965598 | 0.86 | MDM2 (0.68) | MAPTMDM2P4HB | |
| SCHEMBL9965701 | 0.86 | P4HB (0.63) | MDM2P4HB | |
| SCHEMBL9965638 | 0.85 | P4HB (0.58) | TP53MAPTMDM2P4HB | |
| SCHEMBL9965664 | 0.84 | MDM2 (0.75) | TP53MAPTMDM2P4HB | |
| SCHEMBL9965718 | 0.84 | MDM2 (0.67) | TP53MAPTSMN1; SMN2MDM2P4HB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273031-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9238641-B2 | — | — | 2016-01-19 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073858-B2 | Methods of targeted drug development | Errico, Joseph P. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9023354-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | ERRICO, JOSEPH P. | 2015-04-16 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8658170-B2 | Combination therapy with MDM2 and EFGR inhibitors | Errico, Joseph P. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | Errico, Joseph P. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011085126-A2 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | ERRICO JOSEPH P | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120156197-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | TP53 1/4885MAPT 3015/4885SMN1; SMN2 907/4885 |
| US-20110301193-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | TP53 230/4885MAPT 1076/4885SMN1; SMN2 3999/4885 |
| US-20140163069-A1 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | TP53 95/4885MAPT 1268/4885SMN1; SMN2 3974/4885 |
| US-20150105412-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | TP53 1/4885MAPT 3015/4885SMN1; SMN2 907/4885 |
| US-20140134163-A1 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS | TP53, EGFR, MDM2 | TP53 1/4885MAPT 3015/4885SMN1; SMN2 907/4885 |
| US-20140194439-A1 | METHODS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB4 | TP53 192/4885MAPT 1499/4885SMN1; SMN2 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.